MedTrace Logo

Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care

NCT03456349 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-07-20

No results posted yet for this study

Summary

Multi-centre study of HTL0018318 in patients with Alzheimer's disease as an add-on to standard-of-care

Conditions

Interventions

DRUG

HTL0018318

HTL0018318

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Nxera Pharma UK Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-10
Primary Completion
2018-07-16
Completion
2018-07-16

Countries

  • Czechia
  • Poland
  • Slovakia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03456349 on ClinicalTrials.gov